NCT04411706Unknown2 期
a Phase II, Open-label, Single Arm Study of Sintilimab (an Anti-PD-1 Inhibitor) Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma
Xin-Hua Xu1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2020年6月21日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR)
研究概览
简要总结
This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has given written informed consent.
- •Age between 18-75 years old.male or female.
- •Conform to the clinical diagnosis standard strictly or histological or cytological confirmation of HCC(hepatocellular carcinoma) and with at least one measurable lesion by computed tomography (CT) scan or magnetic resonance imaging (MRI) according to RECIST 1.1 standard.
- •Subjects haven't received any systemic treatment that includes target-therapy, immunotherapy or chemotherapy for HCC before admission.
- •liver function status Child-Pugh Class A; Barcelona Clinic Liver Cancer(BCLC) staging is stage B or C；
- •Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1；
- •Expected survival ≥12 weeks
- •The main organ's function is normal and it should meet the following criteria(Excludes use of any blood components and cell growth factors during the screening period):
- •Absolute neutrophil count≥1.5×109 /L
- •Platelets≥80×109/L ;Hemoglobin≥9.0 g/dL; Serum albumin≥3g/dL
- •Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN); ALT and AST≤1.5×upper limit of normal(ULN); AKP≤ 2.5×upper limit of normal(ULN)
- •Thyroid stimulating hormone (TSH)≤1.0×upper limit of normal(ULN)（If abnormal, T3 and T4 levels should be examined at the same time）
- •Serum creatinine ≤1.5×ULN or creatinine clearance > 50 mL/minute (using Cockcroft-Gault formula)
排除标准
- •Patients must not have had prior treatment with Sintilimab or any other PD-L1 or PD-1 antagonists.
- •Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism, except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded.
- •Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. Doses > 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. Note: corticosteroids used for the purpose of IV contrast allergy prophylaxis are allowed.
- •Known history of hypersensitivity to any components of the Sintilimab formulation, or other antibody formulation.
- •Active central nervous system (CNS) metastases with clinical symptoms (including cerebral edema, steroid requirement, or progressive disease).
- •Patients with other malignant tumor (except cured skin basal cell carcinoma and cervical carcinoma).
- •Clinically significant cardiovascular and cerebrovascular diseases, including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, or coronary artery bypass surgery, Congestive heart failure (New York heart association (NYHA) class > 2), ventricular arrhythmia which need medical intervention, left ventricular ejection fraction(LVEF) < 50%.
- •Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents(within 3 months): systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg.
- •Coagulation abnormalities (PT>16s、APTT>43s、TT>21s、Fbg<2g/L), with bleeding tendency or are receiving thrombolytic or anticoagulant therapy. Patients with or previous with serious hemorrhage (bleeding > 30 ml within 3 months), haemoptysis (> 5 ml within 4 weeks) of thromboembolic events within 12 months (including stroke events and/or transient ischemic attack).
- •Previous digestive tract bleeding history within 3 months or evident gastrointestinal bleeding tendency, such as: esophageal varices, local active ulcerative lesions, gastric ulcer and duodenal ulcer, the ulcerous colitis, gastrointestinal diseases such as portal hypertension or resection of tumor with bleeding risk, etc.
- •Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc.
- •History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or active hepatitis (transaminase does not meet the inclusion, hepatitis B virus (HBV) DNA ≥10⁴ /ml or hepatitis C virus (HCV) RNA≥103 /ml or higher)
- •Participated in other clinical trials, or finish other clinical trials within 4 weeks. Patients who may receive other anti-tumor systemic chemotherapy during the study.
- •Patients who may receive vaccination during the study, or previous had vaccination within 4 weeks.
- •Any other medical, psychiatric, or social condition deemed by the investigator to be likely to interfere with a subject's rights, safety, welfare, or ability to sign informed consent, cooperate, and participate in the study or would interfere with the interpretation of the results.
研究组 & 干预措施
Sintilimab+Apatinib+Capecitabine
Experimental
=Drug: Sintilimab（i.v）+apatinib（p.o）+capecitabine（p.o）
干预措施: Sintilimab Combined With Apatinib and Capecitabine (Drug)
结局指标
主要结局
Objective Response Rate (ORR)
时间窗: 1 year after the last patient's enrollment
Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
次要结局
- Duration of Response (DoR)(1 year after the last patient's enrollment)
- Progression-free survival(PFS)(1 year after the last patient's enrollment)
- Overall survival(OS)(1 year after the last patient's enrollment)
- Safety as measured by the rate of AEs(1 year after the last patient's enrollment)
- Disease Control Rate (DCR)(1 year after the last patient's enrollment)
研究者
Xin-Hua Xu
professor
China Three Gorges University, Yichang, China
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)Oral Cavity Squamous Cell CarcinomaOral Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaNCT05098119Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University43
Unknown
2 期
Sintilimab in FH-deficient Renal Cell CarcinomaFH-deficientSintilimabRenal Cell CarcinomaNCT04146831West China Hospital37
招募中
2 期
Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaOral Squamous Cell CarcinomaOropharyngeal Squamous Cell CarcinomaNCT04718415Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University51
招募中
2 期
A Phase II Clinical Study of Sintilimab Combined with Chemotherapy Followed by Concurrent Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (ESCC) (NICE-CS)Esophageal Squamous Cell Carcinoma (ESCC)NCT06709417Shanghai Chest Hospital52
Unknown
2 期
The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue SarcomaSarcoma, Soft TissueNCT04356872Fudan University45